Homocysteine-Lowering Treatment With Folic Acid, Cobalamin, and Pyridoxine Does Not Reduce Blood Markers of Inflammation, Endothelial Dysfunction, or Hypercoagulability in Patients With Previous Transient Ischemic Attack or Stroke
- 1 January 2005
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Stroke
- Vol. 36 (1), 144-146
- https://doi.org/10.1161/01.str.0000150494.91762.70
Abstract
Background and Purpose— Epidemiological and laboratory studies suggest that increasing concentrations of plasma homocysteine (total homocysteine [tHcy]) accelerate cardiovascular disease by promoting vascular inflammation, endothelial dysfunction, and hypercoagulability. Methods— We conducted a randomized controlled trial in 285 patients with recent transient ischemic attack or stroke to examine the effect of lowering tHcy with folic acid 2 mg, vitamin B 12 0.5 mg, and vitamin B 6 25 mg compared with placebo on laboratory markers of vascular inflammation, endothelial dysfunction, and hypercoagulability. Results— At 6 months after randomization, there was no significant difference in blood concentrations of markers of vascular inflammation (high-sensitivity C-reactive protein [ P =0.32]; soluble CD40L [ P =0.33]; IL-6 [ P =0.77]), endothelial dysfunction (vascular cell adhesion molecule-1 [ P =0.27]; intercellular adhesion molecule-1 [ P =0.08]; von Willebrand factor [ P =0.92]), and hypercoagulability (P-selectin [ P =0.33]; prothrombin fragment 1 and 2 [ P =0.81]; D-dimer [ P =0.88]) among patients assigned vitamin therapy compared with placebo despite a 3.7-μmol/L (95% CI, 2.7 to 4.7) reduction in total homocysteine (tHcy). Conclusions— Lowering tHcy by 3.7 μmol/L with folic acid-based multivitamin therapy does not significantly reduce blood concentrations of the biomarkers of inflammation, endothelial dysfunction, or hypercoagulability measured in our study. The possible explanations for our findings are: (1) these biomarkers are not sensitive to the effects of lowering tHcy (eg, multiple risk factor interventions may be required); (2) elevated tHcy causes cardiovascular disease by mechanisms other than the biomarkers measured; or (3) elevated tHcy is a noncausal marker of increased vascular risk.This publication has 6 references indexed in Scilit:
- Homocysteine and markers of coagulation and endothelial cell activationJournal of Thrombosis and Haemostasis, 2004
- Hyperhomocysteinemia, Oxidative Stress, and Cerebral Vascular DysfunctionStroke, 2004
- Reduction of Atherosclerotic Plaques by Lysosomal Acid Lipase SupplementationArteriosclerosis, Thrombosis, and Vascular Biology, 2004
- Homocysteine‐lowering treatment with folic acid plus vitamin B6 lowers urinary albumin excretion but not plasma markers of endothelial function or C‐reactive protein: further analysis of secondary end‐points of a randomized clinical trialEuropean Journal of Clinical Investigation, 2003
- Homocysteine and Risk of Ischemic Heart Disease and StrokeJama-Journal Of The American Medical Association, 2002
- Homocysteine and vascular diseaseThe Lancet, 1999